CN113237966A - 盐酸多西环素的质量检测方法 - Google Patents
盐酸多西环素的质量检测方法 Download PDFInfo
- Publication number
- CN113237966A CN113237966A CN202110377516.8A CN202110377516A CN113237966A CN 113237966 A CN113237966 A CN 113237966A CN 202110377516 A CN202110377516 A CN 202110377516A CN 113237966 A CN113237966 A CN 113237966A
- Authority
- CN
- China
- Prior art keywords
- solution
- concentration
- test
- peak area
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 28
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 229960004082 doxycycline hydrochloride Drugs 0.000 title claims abstract description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000000243 solution Substances 0.000 claims abstract description 51
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000012535 impurity Substances 0.000 claims abstract description 25
- 239000012085 test solution Substances 0.000 claims abstract description 25
- 239000012088 reference solution Substances 0.000 claims abstract description 20
- 238000000926 separation method Methods 0.000 claims abstract description 19
- 238000007865 diluting Methods 0.000 claims abstract description 15
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 11
- 229960003722 doxycycline Drugs 0.000 claims abstract description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000013558 reference substance Substances 0.000 claims abstract description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims abstract description 6
- 229940042016 methacycline Drugs 0.000 claims abstract description 6
- MHIGBKBJSQVXNH-IWVLMIASSA-N methacycline Chemical compound C=C([C@H]1[C@@H]2O)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O MHIGBKBJSQVXNH-IWVLMIASSA-N 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims abstract description 4
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000000945 filler Substances 0.000 claims abstract description 3
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 50
- 239000000523 sample Substances 0.000 claims description 40
- 238000012360 testing method Methods 0.000 claims description 24
- 239000012086 standard solution Substances 0.000 claims description 18
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 16
- 239000012498 ultrapure water Substances 0.000 claims description 16
- 239000012488 sample solution Substances 0.000 claims description 13
- 239000011550 stock solution Substances 0.000 claims description 13
- 238000004817 gas chromatography Methods 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 6
- 230000005526 G1 to G0 transition Effects 0.000 claims description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 6
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 6
- 238000011067 equilibration Methods 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 3
- 230000005540 biological transmission Effects 0.000 claims description 2
- 239000004100 Oxytetracycline Substances 0.000 abstract 1
- 229960000625 oxytetracycline Drugs 0.000 abstract 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 abstract 1
- 235000019366 oxytetracycline Nutrition 0.000 abstract 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 10
- 238000005303 weighing Methods 0.000 description 6
- 239000013557 residual solvent Substances 0.000 description 5
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- RTGDFNSFWBGLEC-TVPGTPATSA-N 2-morpholin-4-ylethyl (z)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1h-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(\C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-TVPGTPATSA-N 0.000 description 2
- 239000012159 carrier gas Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- AAEQXEDPVFIFDK-UHFFFAOYSA-N 3-(4-fluorobenzoyl)-2-(2-methylpropanoyl)-n,3-diphenyloxirane-2-carboxamide Chemical compound C=1C=CC=CC=1NC(=O)C1(C(=O)C(C)C)OC1(C=1C=CC=CC=1)C(=O)C1=CC=C(F)C=C1 AAEQXEDPVFIFDK-UHFFFAOYSA-N 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- GTCCMGFBIWUBLQ-UHFFFAOYSA-N formamide;hydrochloride Chemical compound Cl.NC=O GTCCMGFBIWUBLQ-UHFFFAOYSA-N 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/64—Electrical detectors
- G01N30/68—Flame ionisation detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/045—Standards internal
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
本发明涉及盐酸多西环素的质量检测方法,有关物质检测包括:利用盐酸多西环素系统适用性对照品检测分离条件;利用盐酸多西环素制备供试品溶液,将供试品溶液稀释100倍制成对照溶液;量取同体积的供试品溶液及对照溶液,分离后通过下述公式确定各杂质的含量:杂质含量=(供试品溶液杂质峰面积/对照溶液主峰面积*100)*100%;分离条件如下:填充剂:十八烷基硅烷键合硅胶;流动相包括如下体积份数的各物质:12‑13份乙腈、16‑18份水、34‑36份四丁基硫酸氢铵溶液以及34‑36份乙二胺四乙酸二钠溶液。本发明能够有效检出盐酸多西环素中的杂质β‑多西环素、美他环素、土霉素、2‑乙酰‑2‑脱氨甲酰多西环素,并能有效检测出乙醇、甲醇及丙酮含量。
Description
技术领域
本发明涉及药物质量控制技术领域,具体涉及盐酸多西环素的质量检测方法。
背景技术
盐酸多西环素为光谱抑菌剂,高浓度时具有杀菌作用,本品为6-甲基-4- (二甲氨基)-3,5,10,12,12a-五羟基-1,11-二氧代 -1,4,4a,5,5a,6,11,12a-八氢-2-并四苯甲酰胺盐酸盐半乙醇半水合物。按无水与无乙醇物计算,含多西环素(C22H24N2O8)应为88.0%-94.0%。
发明内容
为了检测盐酸多西环素成品的质量,本发明提供了盐酸多西环素的质量检测方法,包括有关物质检测、乙醇残留量检测以及丙醇和甲醇残留量检测,其中,有关物质检测包括如下步骤:
步骤S1:利用盐酸多西环素系统适用性对照品检测分离条件,其中,杂质β-多西环素与美他环素峰之间的分离度不小于2.0,杂质美他环素与多西环素峰之间的分离度不小于2.0;
步骤S2:利用盐酸多西环素制备供试品溶液,同时,将供试品溶液稀释 100倍制成对照溶液;
步骤S3:量取同体积的供试品溶液及对照溶液,以步骤S1检测好的分离条件分离,通过下述公式确定各杂质的含量:
杂质含量=(供试品溶液杂质峰面积/对照溶液主峰面积*100)*100%;
其中,步骤S1中的分离条件如下:
填充剂:十八烷基硅烷键合硅胶;
柱温:35摄氏度;
检测波长:280nm;
流速:1ml/min;
进样温度:5摄氏度;
流动相包括如下体积份数的各物质:12-13份乙腈、16-18份水、34-36 份四丁基硫酸氢铵溶液以及34-36份乙二胺四乙酸二钠溶液。
其中,四丁基硫酸氢铵溶液浓度介于65-70g/L,且经浓氨水调节pH至 7.0;乙二胺四乙酸二钠溶液的浓度介于110-115g/L,且经浓氨水调节pH 至7.0;
系统适用性对照品溶液、供试品溶液及对照溶液的溶剂均选自浓度为 1g/L的盐酸溶液。
其中,系统适用性对照品溶液浓度介于0.4-0.6mg/ml,供试品溶液浓度介于0.7-0.9mg/ml。
其中,乙醇残留量检测包括如下步骤:
步骤Sa:准备包含预定浓度的正丙醇溶液,作为内标溶液;
步骤Sb:将样品溶于内标溶液中并以超纯水稀释,作为供试品溶液;
步骤Sc:准备包含预定浓度的乙醇溶液,作为对照品贮备液;
步骤Sd:量取预订量的对照品贮备液和内标溶液,并以超纯水稀释,制备包含相同浓度乙醇及正丙醇的对照品溶液;
步骤Se:取相同体积的对照品溶液及供试品溶液,以气相色谱法获取其色谱图,通过下述公式确定样品中残留的乙醇含量:
乙醇残留量=[(对照品正丙醇峰面积/对照品乙醇峰面积)*(供试品乙醇峰面积/供试品正丙醇峰面积)*供试品正丙醇浓度]/供试品样品浓度;
其中,气相色谱法的测定条件如下:
色谱柱固定相选自6%氰丙基苯基-94%二甲基聚硅氧烷;
初始温度为40℃,维持6分钟,以每分钟45℃的速率升温至220℃,维持5分钟;
检测器:氢火焰离子化检测器,检测器温度:250摄氏度;
载体:氮气;流速:3ml/min;
进样口温度200摄氏度;顶空瓶平衡温度80摄氏度,平衡时间45分钟;定量环温度90摄氏度,传输线温度105摄氏度。
其中,丙酮与甲醇的残留量检测包括如下步骤:
步骤Sl:准备包含预定浓度的正丙醇溶液,作为内标溶液;
步骤Sm:将样品溶于内标溶液中并以超纯水稀释,作为供试品溶液;
步骤Sn:准备包含预定浓度的丙酮及甲醇溶液,作为对照品贮备液;
步骤So:量取预订量的对照品贮备液和内标溶液,并以超纯水稀释,制备包含丙酮、甲醇及正丙醇的对照品溶液;
步骤Sp:取相同体积的对照品溶液及供试品溶液,以气相色谱法获取其色谱图,通过下述公式确定样品中残留的丙酮及甲醇含量:
丙酮残留量=[(对照品丙酮浓度/对照品正丙醇浓度)*(对照品正丙醇峰面积/对照品丙酮峰面积)*(供试品丙酮峰面积/供试品正丙醇峰面积)* 供试品正丙醇浓度]/供试品样品浓度;
甲醇残留量=[(对照品甲醇浓度/对照品正丙醇浓度)*(对照品正丙醇峰面积/对照品甲醇峰面积)*(供试品甲醇峰面积/供试品正丙醇峰面积)* 供试品正丙醇浓度]/供试品样品浓度;
其中,气相色谱法的测定条件如下:
色谱柱固定相选自6%氰丙基苯基-94%二甲基聚硅氧烷;
初始温度为40℃,维持6分钟,以每分钟45℃的速率升温至220℃,维持5分钟;
检测器:氢火焰离子化检测器,检测器温度:250摄氏度;
载体:氮气;流速:3ml/min;
进样口温度200摄氏度;顶空瓶平衡温度80摄氏度,平衡时间45分钟。
本发明提供的盐酸多西环素的质量检测方法,能够有效检出盐酸多西环素中的杂质β-多西环素、美他环素、土霉素、2-乙酰-2-脱氨甲酰多西环素,并能有效检测出乙醇、甲醇及丙酮含量。
附图说明
图1:本发明的系统适用性溶液的分离谱图。
图2:本发明的样品溶液的分离谱图。
图3:本发明残留溶剂检测的所涉及的标准溶剂对照品的分离谱图。
图4:本发明的样品的残留溶剂检测谱图。
具体实施方式
为了对本发明的技术方案及有益效果有更进一步的了解,下面结合附图详细说明本发明的技术方案及其产生的有益效果。
一、有关物质检测
用十八烷基硅烷键合硅胶为填充剂(Agilent Eclipse Plus C18 4.6×250mm 5μm或效能相当的色谱柱);以[乙腈-水-(67.9g/L四丁基硫酸氢铵,用浓氨水调节pH值至7.0)-溶液A(称取111.6g乙二胺四乙酸二钠至900ml水中,用浓氨水调节pH值至7.0,加水稀释至 1000ml)](13:17:35:35)为流动相;柱温为35℃;检测波长为280nm;流速为每分钟1ml;进样温度为5℃。称取EP系统适用性对照品(doxycycline for system suitabilityCRS)5mg,加1g/LHCl溶液溶解并稀释至10ml,取20μl 注入液相色谱仪,记录色谱图,EP杂质A峰与EP杂质B峰分离间的分离度应不小于2.0,EP杂质B峰与多西环素峰间的分离度应不小于2.0。
取本品约20.0mg,精密称定,置25ml量瓶中,加1g/L盐酸溶液溶解并稀释至刻度,摇匀,作为供试品溶液;精密量取1ml,用1g/L盐酸溶液稀释至100ml,作为对照溶液。精密量取供试品溶液与对照溶液各20μl,分别注入液相色谱仪,记录色谱图至主成分峰保留时间的2倍。
供试品溶液色谱图中如有杂质峰,EP杂质A峰面积不得大于对照溶液主峰面积2倍(2.0%),EP杂质B峰面积不得大于对照溶液主峰面积0.5倍 (0.5%),EP杂质C峰面积不得大于对照溶液主峰面积0.2倍(0.2%),EP 杂质F峰面积不得大于对照溶液主峰面积(1.0%),其他单个杂质峰不得大于对照品主峰面积0.1倍(0.1%),各杂质峰面积之和不得大于主峰面积的3 倍(3.0%)。供试品溶液色谱图中小于对照品溶液的主峰面积0.05倍(0.05%) 的色谱峰忽略不计。
系统适用性对照品中所涉及到的各杂质如下:
EP杂质A
EP杂质B
EP杂质C
EP杂质D
EP杂质E
EP杂质F
二、乙醇检测
取本品约1.0g,精密称定,置50ml量瓶中,精密加入内标溶液(5mg/ml 正丙醇溶液)10.0ml溶解,用超纯水稀释至刻度,摇匀,作为供试品溶液;精密称取无水乙醇约0.5g,置盛有适量超纯水的100ml量瓶中,加超纯水稀释至刻度,摇匀,作为对照品贮备液;精密量取对照品贮备液和内标溶液各 10ml,置50ml量瓶中,加超纯水稀释至刻度,摇匀,作为对照品溶液。精密量取供试品溶液与对照品溶液各5ml,分别置顶空瓶中,密封。照气相色谱法测定,采用6%氰丙基苯基-94%二甲基聚硅氧烷为固定相的色谱柱 (DB-624,30m×0.53mm,膜厚3.0μm,或效能相当的色谱柱);初始温度为 40℃,维持6分钟,以每分钟45℃的速率升温至220℃,维持5分钟;检测器为氢火焰离子化检测器(FID),检测器温度为250℃;以氮气为载气,流速为每分钟3ml;进样口温度为200℃;顶空瓶平衡温度为80℃,平衡时间为45分钟,定量环温度为90℃,传输线温度为105℃。分别取对照品溶液和供试品溶液分别顶空进样,记录色谱图。按内标法以峰面积比值计算,含乙醇的量应为4.3%~6.0%。
三、残留溶剂丙酮与甲醇检测
取本品约1.0g,精密称定,置50ml量瓶中,精密加入内标溶液(5mg/ml 正丙醇溶液)10.0ml溶解,用超纯水稀释至刻度,摇匀,作为供试品溶液;分别精密称取丙酮约50mg、甲醇约50mg,置盛有适量超纯水的100ml量瓶中,加超纯水稀释至刻度,摇匀,作为对照品贮备液;精密量取对照品贮备液和内标溶液各10ml,置50ml量瓶中,加超纯水稀释至刻度,摇匀,作为对照品溶液。精密量取供试品溶液与对照品溶液各5ml,分别置顶空瓶中,密封。照气相色谱法测定,采用6%氰丙基苯基-94%二甲基聚硅氧烷为固定相的色谱柱(DB-624,30m×0.53mm,膜厚3.0μm,或效能相当的色谱柱);初始温度为40℃,维持6分钟,以每分钟45℃的速率升温至220℃,维持5分钟;检测器为氢火焰离子化检测器(FID),检测器温度为250℃;以氮气为载气,流速为每分钟3ml;进样口温度为200℃;顶空瓶平衡温度为 80℃,平衡时间为45分钟。取对照品溶液顶空进样,各成分峰之间的分离度应符合要求。再取供试品溶液与对照品溶液分别顶空进样,记录色谱图。按外标法以峰面积分别计算,丙酮的残留量不得过0.5%,甲醇的残留量不得过0.3%。
图3为本发明的残留溶剂检测中所涉及的溶剂的对照品的谱图,图4为本发明的样品的残留溶剂检测谱图,由图4中可看出,本发明的样品中含有少量乙醇残留,不含甲醇及丙酮残留。
虽然本发明已利用上述较佳实施例进行说明,然其并非用以限定本发明的保护范围,任何本领域技术人员在不脱离本发明的精神和范围之内,相对上述实施例进行各种变动与修改仍属本发明所保护的范围,因此本发明的保护范围以权利要求书所界定的为准。
Claims (5)
1.盐酸多西环素的质量检测方法,包括有关物质检测、乙醇残留量检测以及丙醇和甲醇残留量检测,其中,有关物质检测包括如下步骤:
步骤S1:利用盐酸多西环素系统适用性对照品检测分离条件,其中,杂质β-多西环素与美他环素峰之间的分离度不小于2.0,杂质美他环素与多西环素峰之间的分离度不小于2.0;
步骤S2:利用盐酸多西环素制备供试品溶液,同时,将供试品溶液稀释100倍制成对照溶液;
步骤S3:量取同体积的供试品溶液及对照溶液,以步骤S1检测好的分离条件分离,通过下述公式确定各杂质的含量:
杂质含量=(供试品溶液杂质峰面积/对照溶液主峰面积*100)*100%;
其中,步骤S1中的分离条件如下:
填充剂:十八烷基硅烷键合硅胶;
柱温:35摄氏度;
检测波长:280nm;
流速:1ml/min;
进样温度:5摄氏度;
流动相包括如下体积份数的各物质:12-13份乙腈、16-18份水、34-36份四丁基硫酸氢铵溶液以及34-36份乙二胺四乙酸二钠溶液。
2.如权利要求1所述的盐酸多西环素的质量检测方法,其特征在于:四丁基硫酸氢铵溶液浓度介于65-70g/L,且经浓氨水调节pH至7.0;乙二胺四乙酸二钠溶液的浓度介于110-115g/L,且经浓氨水调节pH至7.0;
系统适用性对照品溶液、供试品溶液及对照溶液的溶剂均选自浓度为1g/L的盐酸溶液。
3.如权利要求1所述的盐酸多西环素的质量检测方法,其特征在于:系统适用性对照品溶液浓度介于0.4-0.6mg/ml,供试品溶液浓度介于0.7-0.9mg/ml。
4.如权利要求1所述的盐酸多西环素的质量检测方法,其特征在于:乙醇残留量检测包括如下步骤:
步骤Sa:准备包含预定浓度的正丙醇溶液,作为内标溶液;
步骤Sb:将样品溶于内标溶液中并以超纯水稀释,作为供试品溶液;
步骤Sc:准备包含预定浓度的乙醇溶液,作为对照品贮备液;
步骤Sd:量取预订量的对照品贮备液和内标溶液,并以超纯水稀释,制备包含相同浓度乙醇及正丙醇的对照品溶液;
步骤Se:取相同体积的对照品溶液及供试品溶液,以气相色谱法获取其色谱图,通过下述公式确定样品中残留的乙醇含量:
乙醇残留量=[(对照品正丙醇峰面积/对照品乙醇峰面积)*(供试品乙醇峰面积/供试品正丙醇峰面积)*供试品正丙醇浓度]/供试品样品浓度;
其中,气相色谱法的测定条件如下:
色谱柱固定相选自6%氰丙基苯基-94%二甲基聚硅氧烷;
初始温度为40℃,维持6分钟,以每分钟45℃的速率升温至220℃,维持5分钟;
检测器:氢火焰离子化检测器,检测器温度:250摄氏度;
载体:氮气;流速:3ml/min;
进样口温度200摄氏度;顶空瓶平衡温度80摄氏度,平衡时间45分钟;定量环温度90摄氏度,传输线温度105摄氏度。
5.如权利要求1所述的盐酸多西环素的质量检测方法,其特征在于:丙酮与甲醇的残留量检测包括如下步骤:
步骤Sl:准备包含预定浓度的正丙醇溶液,作为内标溶液;
步骤Sm:将样品溶于内标溶液中并以超纯水稀释,作为供试品溶液;
步骤Sn:准备包含预定浓度的丙酮及甲醇溶液,作为对照品贮备液;
步骤So:量取预订量的对照品贮备液和内标溶液,并以超纯水稀释,制备包含丙酮、甲醇及正丙醇的对照品溶液;
步骤Sp:取相同体积的对照品溶液及供试品溶液,以气相色谱法获取其色谱图,通过下述公式确定样品中残留的丙酮及甲醇含量:
丙酮残留量=[(对照品丙酮浓度/对照品正丙醇浓度)*(对照品正丙醇峰面积/对照品丙酮峰面积)*(供试品丙酮峰面积/供试品正丙醇峰面积)*供试品正丙醇浓度]/供试品样品浓度;
甲醇残留量=[(对照品甲醇浓度/对照品正丙醇浓度)*(对照品正丙醇峰面积/对照品甲醇峰面积)*(供试品甲醇峰面积/供试品正丙醇峰面积)*供试品正丙醇浓度]/供试品样品浓度;
其中,气相色谱法的测定条件如下:
色谱柱固定相选自6%氰丙基苯基-94%二甲基聚硅氧烷;
初始温度为40℃,维持6分钟,以每分钟45℃的速率升温至220℃,维持5分钟;
检测器:氢火焰离子化检测器,检测器温度:250摄氏度;
载体:氮气;流速:3ml/min;
进样口温度200摄氏度;顶空瓶平衡温度80摄氏度,平衡时间45分钟。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110377516.8A CN113237966A (zh) | 2021-04-08 | 2021-04-08 | 盐酸多西环素的质量检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110377516.8A CN113237966A (zh) | 2021-04-08 | 2021-04-08 | 盐酸多西环素的质量检测方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113237966A true CN113237966A (zh) | 2021-08-10 |
Family
ID=77131265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110377516.8A Pending CN113237966A (zh) | 2021-04-08 | 2021-04-08 | 盐酸多西环素的质量检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113237966A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114839279A (zh) * | 2022-02-21 | 2022-08-02 | 佛山市南海北沙制药有限公司 | 一种乙烯基乙醚中杂质含量的测定方法 |
CN117630202A (zh) * | 2023-10-25 | 2024-03-01 | 山东泰合医药科技有限公司 | 盐酸丁螺环酮中间体杂质的检测方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111443139A (zh) * | 2020-03-13 | 2020-07-24 | 扬州联博药业有限公司 | 一种同时检测盐酸多西环素中多西环素及有关物质相对保留时间和峰纯度的方法 |
-
2021
- 2021-04-08 CN CN202110377516.8A patent/CN113237966A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111443139A (zh) * | 2020-03-13 | 2020-07-24 | 扬州联博药业有限公司 | 一种同时检测盐酸多西环素中多西环素及有关物质相对保留时间和峰纯度的方法 |
Non-Patent Citations (3)
Title |
---|
YARRAMRAJU SITARAMARAJU 等: "Evaluation of the European Pharmacopoeia method for control of residual solvents in some antibiotics", 《JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 》 * |
安彦 等: "顶空毛细管气相色谱法测定地塞米松磷酸钠有机溶剂残留量", 《天津药学》 * |
欧洲药典委员会: "DOXYCYCLINE HYCLATE", 《EUROPEAN PHARMACOPOEIA 10.0》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114839279A (zh) * | 2022-02-21 | 2022-08-02 | 佛山市南海北沙制药有限公司 | 一种乙烯基乙醚中杂质含量的测定方法 |
CN117630202A (zh) * | 2023-10-25 | 2024-03-01 | 山东泰合医药科技有限公司 | 盐酸丁螺环酮中间体杂质的检测方法 |
CN117630202B (zh) * | 2023-10-25 | 2024-06-11 | 山东泰合医药科技有限公司 | 盐酸丁螺环酮中间体杂质的检测方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108226309B (zh) | 一种右丙亚胺的分析方法 | |
CN113237966A (zh) | 盐酸多西环素的质量检测方法 | |
Uno et al. | Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection | |
Bühring et al. | Determination of the new β-blocker bisoprolol and of metoprolol, atenolol and propranolol in plasma and urine by high-performance liquid chromatography | |
CN109725073B (zh) | 乙酰半胱氨酸对映异构体的分离检测方法 | |
Tseng et al. | Determination of sildenafil citrate adulterated in a dietary supplement capsule by LC/MS/MS | |
WO2020187644A1 (en) | Method for the detection and quantification of fosmomycin, impurities and degradation products thereof | |
CN111551654A (zh) | 检测头孢克肟聚合物杂质的方法 | |
da Silva Gonçalves et al. | Development and validation of a fast HPLC method for methyldopa enantiomers using superficially porous particle based macrocyclic glycopeptide stationary phase | |
CN109900830B (zh) | 采用hplc分离测定塞来昔布中磺酰胺类杂质的方法及应用 | |
CN109490444B (zh) | 一种hplc法分离测定度他雄胺原料药及制剂中降解杂质的方法 | |
CN102288687A (zh) | 一种门冬氨酸鸟氨酸杂质的分析检测方法 | |
CN107179369B (zh) | 一种运用高效液相色谱检测盐酸胍法辛有关物质的方法 | |
CN101963603B (zh) | 用hplc法分析精氨酸、盐酸精氨酸原料及制剂的方法 | |
Oertel et al. | Elucidation of the structure of talinolol metabolites in man determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum | |
Li et al. | Pulse gradient, large-volume injection, high-throughput ultra-performance liquid chromatographic/tandem mass spectrometry bioanalysis for measurement of plasma amrubicin and its metabolite amrubicinol | |
CN113125583A (zh) | 一种注射用泮托拉唑钠中基因毒性杂质含量的检测方法 | |
CN111060621A (zh) | 一种注射用头孢哌酮钠舒巴坦钠有关物质的检测方法 | |
CN112986432B (zh) | 一种2,4-二氨基-6-氯嘧啶有关物质的检测方法及其应用 | |
CN110412164B (zh) | 一种盐酸美西律的有关物质的检测方法 | |
Naidong et al. | Determination of metacycline and related substances by column liquid chromatography on poly (styrene-divinylbenzene) | |
Mehvar | Liquid chromatographic analysis of propafenone enantiomers in human plasma | |
Varvara et al. | ION-PAIR REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY OF ONDANSETRON HYDROCHLORIDE USING SODIUM HEPTANESULPHONATE AS A COUNTERION | |
Agarwal et al. | Potential of RP-HPLC-DAD-MS for the qualitative and quantitative analysis of dapagliflozin in tablets and degradants | |
Younus et al. | Determination of venlafaxine and modafinil in individual tablet dosage forms using single RP-HPLC method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210810 |